N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway

BACKGROUND: MYCN amplification or N-Myc overexpression is found in approximately 40% NEPC and up to 20% CRPC patients. N-Myc has been demonstrated to drive disease progression and hormonal therapeutic resistance of NEPC/CRPC. Here, we aim to identify the molecular mechanisms underlying the N-Myc-dri...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Yu, Xu, Lingfan, Chang, Yan, Zeng, Tao, Chen, Xufeng, Wang, Aifeng, Groth, Jeff, Foo, Wen-Chi, Liang, Chaozhao, Hu, Hailiang, Huang, Jiaoti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6337850/
https://www.ncbi.nlm.nih.gov/pubmed/30657058
http://dx.doi.org/10.1186/s12943-019-0941-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6337850/
https://www.ncbi.nlm.nih.gov/pubmed/30657058
http://dx.doi.org/10.1186/s12943-019-0941-2

Ejemplares similares